2-Methoxystypandrone represses RANKL-mediated osteoclastogenesis by down-regulating formation of TRAF6-TAK1 signalling complexes

British Journal of Pharmacology

Volumn 161, Issue 2, 2010, Pages 321-335

  Chiou, W F ^a,b   Liao, J F ^c   Huang, C Y ^c   Chen, C C ^d  

^a NATIONAL RESEARCH INSTITUTE OF CHINESE MEDICINE   (Taiwan)

^b NATIONAL TAITUNG UNIVERSITY   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d HUNGKUANG UNIVERSITY   (Taiwan)

Author keywords

2 methoxystypandrone; bone resorption; c Fos; DC STAMP; MMP 9; NF B; NFATc1; osteoclastogenesis; TAK1; TRAF6

Indexed keywords

2 METHOXYSTYPANDRONE; ACTIN; DENDRITIC CELL SPECIFIC TRANSMEMBRANE PROTEIN; GELATINASE B; I KAPPA B; MEMBRANE PROTEIN; MESSENGER RNA; NAPHTHOQUINONE; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN C FOS; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR NFATC1; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BONE MARROW CELL; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOTOXICITY; DENDRITIC CELL; DOWN REGULATION; DRUG TARGETING; ENZYME PHOSPHORYLATION; GENE ACTIVATION; GENE EXPRESSION; GENE REPRESSION; MALE; MOUSE; MULTINUCLEAR CELL; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; POLYGONUM CUSPIDATUM; PRIORITY JOURNAL; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANIMALS; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; CELL DIFFERENTIATION; CELL LINE; DOWN-REGULATION; DRUGS, CHINESE HERBAL; MACROPHAGES; MAP KINASE KINASE KINASES; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; NAPHTHOQUINONES; OSTEOCLASTS; POLYGONUM CUSPIDATUM; PROTEASE INHIBITORS; PROTEIN BINDING; RANK LIGAND; SIGNAL TRANSDUCTION; TNF RECEPTOR-ASSOCIATED FACTOR 6;

EID: 77956017200     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.00823.x     Document Type: Article

References (42)

1. Alemayehu G, Abegaz B, Snatzke G, Duddeck H (1993). Bianthrones from Senna longiracemosa. Phytochemistry 32 : 1273 1277.
2. Alliston T, Derynck R (2002). Medicine: interfering with bone remodelling. Nature 416 : 686 687.
3. Asagiri M, Takayanagi H (2007). The molecular understanding of osteoclast differentiation. Bone 40 : 251 264.
4. Asagiri M, Sato K, Usami T, Ochi S, Nishina H, Yoshida H et al. (2005). Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J Exp Med 202 : 1261 1269.
5. Boyce BF, Yamashita T, Yao Z, Zhang Q, Li F, Xing L (2005). Roles for NF-κB and c-Fos in osteoclasts. J Bone Miner Metab 23 : 11 15.
6. Boyle WJ, Simonet WS, Lacey DL (2003). Osteoclast differentiation and activation. Nature 423 : 337 342.
7. Chiou WF, Chen CC (2009). 8-Prenylkaempferol suppresses influenza A virus-induced RANTES production in A549 cells via blocking PI3K-mediated transcriptional activation of NF-κB and IRF3. Evid Based Complement Alternat Med Epub ahead of print BG, Haridas V, Ni J, Moore PA, Aggarwal BB (1998). Characterization of the intracellular domain of receptor activator of NF-κB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-κB and c-Jun N-terminal kinase. J Biol Chem 273 : 20551 20555.
8. Delaissé JM, Engsig MT, Everts V, del Carmen Ovejero M, Ferreras M, Lund L et al. (2000). Proteinases in bone resorption: obvious and less obvious roles. Clin Chim Acta 291 : 223 234.
9. Dougall WC, Glaccum M, Charrier K, Rohrbach K, Brasel K, De Smedt T et al. (1999). RANK is essential for osteoclast and lymph node development. Genes Dev 13 : 2412 2424.
10. Engsig MT, Chen QJ, Vu TH, Pedersen AC, Therkidsen B, Lund LR et al. (2000). Matrix metalloproteinase 9 and vascular endothelial growth factor are essential for osteoclast recruitment into developing long bones. J Cell Biol 151 : 879 889.
11. Feng X (2005). RANKing intracellular signaling in osteoclast. IUBMB Life 57 : 389 395.
12. Fuller K, Wong B, Fox S, Choi Y, Chambers TJ (1998). TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med 188 : 997 1001.
13. Grigoriadis AE, Wang ZQ, Cecchini MG, Hofstetter W, Felix R, Fleisch HA et al. (1994). c-Fos: a key regulator of osteoclast/macrophage lineage determination and bone remodeling. Science 266 : 443 448.
14. Iotsova V, Caamano J, Loy J, Yang Y, Lewin A, Bravo R (1997). Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. Nat Med 3 : 1285 1289.
15. Ishida N, Hayashi K, Hoshijima M, Ogawa T, Koga S, Miyatake Y et al. (2002). Large scale gene expression analysis of osteoclastogenesis in vitro and elucidation of NFAT2 as a key regulator. J Biol Chem 277 : 41147 41156.
16. Jurdic P, Saltel F, Chabadel A, Destaing O (2006). Podosome and sealing zone: specificity of the osteoclast model. Eur J Cell Biol 85 : 195 202.
17. Kim HH, Lee DE, Shin JN, Lee YS, Jeon YM, Chung CH et al. (1999). Receptor activator of NF-κB recruits multiple TRAF family adaptors and activates c-Jun N-terminal kinase. FEBS Lett 443 : 297 302.
18. Kim K, Kim JH, Lee J, Jin HM, Lee SH, Fisher DE et al. (2005). Nuclear factor of activated T cells c1 induces osteoclast-associated receptor gene expression during tumor necrosis factor-related activation-induced cytokine-mediated osteoclastogenesis. J Biol Chem 280 : 35209 35216.
19. Kim K, Lee SH, Ha Kim J, Choi Y, Kim N (2008). NFATc1 induces osteoclast fusion via up-regulation of Atp6v0d2 and the dendritic cell-specific transmembrane protein (DC-STAMP). Mol Endocrinol 22 : 176 185.
20. Kim YM, Lee CH, Kim HG, Lee HS (2004). Anthraquinones isolated from Cassia tora (Leguminosae) seed show an antifungal property against Phytopathogenic fungi. J Agric Food Chem 52 : 6096 6100.
21. Lee SW, Han SI, Kim HH, Lee ZH (2002). TAK1-dependent activation of AP-1 and c-Jun N-terminal kinase by receptor activator of NF-kappaB. J Biochem Mol Biol 35 : 371 376.
22. Lee ZH, Kim HH (2003). Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts. Biochem Biophys Res Commun 305 : 211 214.
23. Li X, Udagawa N, Itoh K, Suda K, Murase Y, Nishihara T et al. (2002). p38 MAPK-mediated signals are required for inducing osteoclast differentiation but not for osteoclast function. Endocrinology 143 : 3105 3113.
24. Lomaga MA, Yeh WC, Sarosi I, Duncan GS, Furlonger C, Ho A et al. (1999). TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev 13 : 1015 1024.
25. Milner JM, Rowan AD, Elliott SF, Cawston TE (2003). Inhibition of furinlike enzymes blocks interleukin-1alpha/oncostatin M-stimulated cartilage degradation. Arthritis Rheum 8 : 1057 1066.
26. Miyamoto T, Suda T (2003). Differentiation and function of osteoclasts. Keio J Med 52 : 1 7.
27. Mizukami J, Takaesu G, Akatsuka H, Sakurai H, Ninomiya-Tsuji J, Matsumoto K et al. (2002). Receptor Activator of NF-κB Ligand (RANKL) Activates TAK1 mitogen-activated protein kinase kinase kinase through a signaling complex containing RANK, TAB2, and TRAF6. Mol Cell Biol 9 : 992 1000.
28. Ninomiya-Tsuji J, Kishimoto K, Hiyama A, Inoue J, Cao Z, Matsumoto K (1999). The kinase TAK1 can activate the NIK-IκB as well as the MAP kinase cascade in the IL-1 signaling pathway. Nature 398 : 252 256.
29. Ortega N, Behonick D, Stickens D, Werb Z (2003). How proteases regulate bone morphogenesis. Ann N Y Acad Sci 995 : 109 116.
30. Shiotani A, Takami M, Itoh K, Shibasaki Y, Sasaki T (2002). Regulation of osteoclast differentiation and function by receptor activator of NF-κB ligand and osteoprotegerin. Anat Rec 268 : 137 146.
31. Singh SB, Graham PL, Reamer RA, Cordingley MG (2001). Discovery, total synthesis, HRV 3C-protease inhibitory activity, and structure-activity relationships of 2-methoxystypandrone and its analogues. Bioorg Med Chem Lett 11 : 3143 3146.
32. Suda T, Takahashi N, Udagawa E, Jimi E, Gillespie MT, Martin TJ (1999). Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 20 : 345 357.
33. Takayanagi H (2007). The role of NFAT in osteoclast formation. Ann N Y Acad Sci 116 : 227 237.
34. Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H et al. (2002). Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling for terminal differentiation of osteoclasts. Dev Cell 3 : 889 901.
35. Teitelbaum SL (2000). Bone resorption by osteoclasts. Science 289 : 1504 1508.
36. Teitelbaum SL, Ross FP (2003). Genetic regulation of osteoclast development and function. Nat Rev Genet 4 : 638 649.
37. Wagner EF, Eferl R (2005). Fos/AP-1 proteins in bone and the immune system. Immunol Rev 208 : 126 140.
38. Wang ZQ, Ovitt C, Grigoriadis AE, Mohle-Steinlein U, Ruther U, Wagner EF (1992). Bone and haematopoietic defects in mice lacking c-fos. Nature 360 : 741 745.
39. Yagi M, Miyamoto T, Sawatani Y, Iwamoto K, Hosogane N, Fujita N et al. (2005). DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells. J Exp Med 202 : 345 351.
40. Yagi M, Ninomiya K, Fujita N, Suzuki T, Iwasaki R, Morita K et al. (2007). Induction of DC-STAMP by alternative activation and downstream signaling mechanisms. J Bone Miner Res 22 : 992 1001.
41. Yamaguchi K, Shirakabe K, Shibuya H, Irie K, Oishi I, Ueno N et al. (1995). Identification of a member of the MAPKKK family as a potential mediator of TGF-β signal transduction. Science 270 : 2008 2011.
42. Yamashita T, Yao Z, Li F, Zhang Q, Badell IR, Schwarz EM et al. (2007). NF-κB p50 and p52 regulate RANKL and TNF-induced osteoclast precursor differentiation by activating c-Fos and NFATc1. J Biol Chem 282 : 18245 18253.